Short Interest in BioStem Technologies, Inc. (OTCMKTS:BSEM) Rises By 32.3%

BioStem Technologies, Inc. (OTCMKTS:BSEM) saw a large growth in short interest in January. As of January 30th, there was short interest totaling 406,408 shares, a growth of 32.3% from the January 15th total of 307,219 shares. Approximately 2.4% of the company’s stock are short sold. Based on an average daily volume of 495,453 shares, the days-to-cover ratio is currently 0.8 days. Based on an average daily volume of 495,453 shares, the days-to-cover ratio is currently 0.8 days. Approximately 2.4% of the company’s stock are short sold.

BioStem Technologies Stock Performance

Shares of BioStem Technologies stock opened at $5.80 on Monday. BioStem Technologies has a 52 week low of $3.09 and a 52 week high of $15.74. The stock has a 50 day moving average price of $4.96 and a two-hundred day moving average price of $5.45. The stock has a market capitalization of $97.56 million, a PE ratio of 6.82 and a beta of -0.39.

BioStem Technologies (OTCMKTS:BSEM) last released its quarterly earnings data on Thursday, November 13th. The company reported $0.03 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.01. The business had revenue of $10.47 million for the quarter, compared to analyst estimates of $55.20 million. Research analysts forecast that BioStem Technologies will post 1.41 EPS for the current year.

BioStem Technologies Company Profile

BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr.